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Background: Although several single-nucleotide polymorphisms in microRNA (miRNA) genes have been associated
with primary hepatocellular carcinoma, published findings regarding this relationship are inconsistent and inconclusive.
Methods: The high-resolution melting (HRM) analysis was used to determine whether the occurrence of the SNPs of
miR-146a C > G (rs2910164), miR-196a2 C > T (rs11614913), miR-301b A > G (rs384262), and miR-499 C > T (rs3746444)
differs in frequency-matched 314 HCC patients and 407 controls by age and sex.
Results: The groups’ genotype distributions of miR-196a2 C > T and miR-499 C > T differed significantly (P < 0.01), both
of them increased the risk of HCC in different dominant genetic models (P < 0.01); compared with individuals carrying
one or neither of the unfavorable genotypes, individuals carrying both unfavorable genotypes (CT + CC) had a 3.11-fold
higher HCC risk (95% confidence interval (CI), 1.89–5.09; P = 7.18 × 10−6). Moreover, the allele frequency of miR-499
C > T was significantly different between the two groups, and the HCC risk of carriers of the C allele was higher than
that of carriers of the T allele (odds ratio, 1.53; 95% CI, 1.15-2.03; P = 0.003). Further, we found that the activated
partial thromboplastin time (APTT) in HCC patients with miR-196a2 CC genotype was longer than patients with TT
genotypes (P < 0.05), and HCC patients with miR-499 C allele had higher serum levels of direct bilirubin, globulin,
γ-glutamyltranspeptidase, alkaline phosphatase, and lower serum cholinesterase (P < 0.05).
Conclusions: Our findings suggest that the SNPs in miR-196a2 C > T and miR-499 C > T confer HCC risk and that affect
the clinical laboratory characteristics of HCC patients.
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Hepatocellular carcinoma (HCC) is the third most
common cause of cancer-related mortality worldwide
[1]. In the United States, approximately 6,000 new
HCC cases are diagnosed each year. HCC is not a
chemosensitive tumor, and most HCCs are diagnosed
at an advanced stage, which often renders intervention
ineffective, thereby leading to a high mortality rate [2].
The main known risk factors for HCC are hepatitis B and
hepatitis C infection; other key risk factors, which vary
from country to country, include exposure to aflatoxin B1,* Correspondence: smliu@whu.edu.cn
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unless otherwise stated.excessive alcohol consumption, smoking, diabetes, male
sex, and genetic factors [3-5].
Previous studies have shown that single-nucleotide
polymorphisms (SNPs) in microRNAs (miRNAs) may
contribute to tumorigenesis owing to their ability to
change the expression, regulation, and/or function of
miRNAs [6-9]. miRNAs are a class of small, non-coding
RNAs 17–25 nucleotides in length that are conserved
across species and can regulate gene expression by binding
to complementary sequences in the 3′- untranslated
regions of target mRNAs [6,9]. As oncogenes or tumor
suppressor genes, miRNAs play important roles in
human cancer progression, affecting tumor invasiveness,
metastasis, EMT and other clinical characteristics [9].
Genetic variations in miRNAs are confirmed to relate with
renal cell carcinoma [10], non-small cell lung cancer [11],This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[17,18], gastric cancer [19,20], colorectal cancer [21,22],
cervical squamous cell carcinoma [23], ovarian cancer
[24], papillary thyroid carcinoma [25], adult glioma [26]
and oral cancer [27]. However, the exact mechanism by
which miRNA expression levels are altered in different
cancers remains unknown. Researchers have recently
proposed that a large number of potentially functional
miRNA-related SNPs are potential cancer biomarkers.
Among these, the SNPs in miR-146a C > G, miR-196a2
C > T, and miR-499 C > T, which have been reported to be
associated with liver cancer [12-15], breast cancer [17,18],
gastric cancer [19,20] and colorectal cancer [21,22]. In
particular, the rs11614913 SNP in miR-196a2 [12,15], the
rs2910164 SNP in miR-146a [14,15] and the rs3746444
SNP in miR-499 [13] are likely associated with HCC risk.
miR-499 C > T may play an important role in HCC
pathogenesis by regulating ets1, which plays a fundamental
role in extracellular matrix degradation, a process required
for tumor cell invasion and migration [28]. The rs3746444
SNP in miR-499 C >T has also been associated with
susceptibility to hepatitis B virus–related HCC [13].
Guo et al. also found the significant association between
the SNP in miR-196a2 and increased susceptibility to
colorectal cancer and HCC [16]. miR-146a also played key
roles in regulating the angiogenic activity of endothelial
cells in HCC through BRCA1-PDGFRA pathway and
regulating the sensitivity of HCC cells to the cytotoxic
effects of IFN-α through SMAD4 [29,30]. The C > G
polymorphism of miR-146 precursor affects the production
of mature miR-146a and is associated with the risks
of HCC, adult glioma and gastric cancer [14,20,26]. miR-
301 is an interesting miRNA, which was differentially
expressed in HCC compared with adjacent benign
liver [31] and was down-regulated in HCV-infected
Huh7.5 cells and subsequently up-regulated following
interferon-α treatment [32].
However, the meta-analysis revealed that the miR-146a
C >G (rs2910164) variant was associated with a decreased
HCC risk among Asian and male populations and no
significant association was observed between the SNP
and risk for HCC in the female populations [15]. They
have not found a linkage between miRNA-related SNPs
and HCC, such as no significant association between
the SNP of miR-146a C > G and HCC risk [13,33], no
significant correlation between the miR-499 rs3746444
polymorphism and HCC risk [15,33], and no significant
association between the miR-196a2 SNP and the risk of
hepatitis B virus–related HCC [12]. Even if HCC risk was
significantly lower in male patients with the miR-196a2
TT genotype or T allele than those with CC genotype or C
allele [12], carriers of the miR-196a2 (rs11614913) T allele
were confirmed to associate with susceptibility to HCC
among Caucasian populations [15].Although previous studies analyzed the relationship
between different miR-499, miR-196a2 and miR-146a
genotypes in different patient populations, their findings
were inconsistent, and they did not investigate whether
the genotypes affected patients’ clinical characteristics.
To determine the role of miRNA SNPs in HCC, we
performed a case–control study in which we used a
high-resolution melting (HRM) genotyping method to
investigate the relationship between the SNPs of four
miRNAs (miR-146a C > G, miR-196a2 C > T, miR-301b
A >G, and miR-499 C > T) (Additional file 1: Table S1)
and HCC. We also analyzed the clinical characteristics of
HCC patients with different genotypes to determine the
role of miRNA SNPs in HCC.
Methods
Study population
The ethics committee of Zhongnan Hospital of Wuhan
University has approved the present study (Approval
Number 2013059). Informed consent was obtained from all
participants at interview, as well as at time of biospecimen
collection. We included 314 patients who were diagnosed
with HCC at Zhongnan Hospital between 2005 and 2012.
All patients had pathologically confirmed HCC and
underwent liver resection. The American Joint Committee
on Cancer’s TNM (tumor, node, and metastasis) staging
system and the Barcelona Clinic Liver Cancer (BCLC)
staging system were used to stage patients’ HCC.
From these patients we collected 314 formalin-fixed,
paraffin-embedded (FFPE) tissue samples (6 mm× 6 mm;
about 5 μm thick). The control group consisted of 407
participants randomly selected from healthy individuals
enrolled in an HCC screening program who had no history
of cancer or chronic disease. Ethylenediaminetetraacetic
acid–anticoagulated peripheral blood samples were
collected from the control group. Additionally, we collected
39 tumor tissue samples and peripheral blood samples
from the same HCC patients. All participants’ hepatitis B
surface antigen/hepatitis B virus statuses were assessed
by a chemiluminescent enzyme immunoassay. The
available preoperative biometrical characteristics and
clinical data of the HCC patients and controls are shown
in Additional file 1: Table S2.
DNA extraction
We used commercially available DNA extraction kits
to extract genomic DNA from FFPE tissue samples
(Paraffin-Embedded Tissue Kit, TaKaRa, Dalian, China) or
peripheral blood samples (TIANamp Blood DNA Kit,
Tiangen, Beijing, China) according to the manufacturer’s
instructions. We used a DU 530 spectrophotometer
(Beckman Coulter, Fullerton, CA, USA) to quantify the
concentration of DNA; absorbance readings of the DNA
extracts at 260 nm indicated that the DNA concentration
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were frozen at −20°C without repeated freeze-thawing
cycles until subjected to assay.
SNP genotyping
To genotype the four SNPs, we performed HRM of
small amplicons using the LightScanner 32 system
(Idaho Technology, Salt Lake City, UT, USA) in tumor and
blood samples from HCC patients. We initially tested the
concordance between genotypes from 39 paired tumor and
blood samples using the k statistic. Then, we investigated
the four miRNAS’ SNPs in the population of 314 HCC
patients with FFPE samples, and 407 controls with
peripheral blood samples. The primers used for the
HRM analysis are shown in Additional file 1: Table S3.
The amplifications were performed in 10-μL volumes
containing 10–20 ng of genomic DNA, 0.16 μM pri-
mer, 250 μM of each deoxynucleotide triphosphate,
1.25 μM Mg2+, 2 μL of 5× polymerase chain reaction
buffer, 1.0 U of polymerase enzyme, and 1× LCGreen
Plus + dye (Idaho Technology). Polymerase chain reac-
tion cycling included an initial denaturation at 95°C
for 2 min followed by 45 cycles of 15 seconds at 95°C,
15 seconds at the respective annealing temperatures
(Additional file 1: Table S3), and 15 seconds at 72°C
and final extensions of 30 seconds at 94°C and 30 seconds
at 28°C for heteroduplex formation.
For quality control, DNA samples with different known
genotypes were included as internal standards in each
experiment. A duplicate control without a DNA template
was also included in each run to test for contamination
and to assess the formation of any primer dimer.
Statistical analysis
We used the statistical software program SPSS 17.0 for
Windows to perform all statistical analyses (SPSS Inc.,
Chicago, IL). Differences in the clinical characteristics
and genotypes between the HCC patients and control
participants were evaluated using the Student t-test or
one-way ANOVA (for continuous variables) and Pearson
chi-square test (for categorical variables). The Pearson
chi-square test was also used to determine whether
the allele frequencies in the control group were in
Hardy-Weinberg equilibrium (HWE). We used logistic re-
gression analysis with adjustment for possible confounders
(sex and age) to determine whether the genotypes of the
four SNPs were associated with HCC risk; the results are
presented as odds ratios (ORs) and 95% confidence
intervals (CIs). To compare the clinical characteristics
of HCC patients who had different genotypes, we per-
formed a K-independent non-parametric analysis for
skewed distribution. We also used SNPStats, a Web-based
SNP analysis software program (http://bioinfo.iconcologia.
net/snpstats/start.htm), to analyze the four miRNAs’ SNPs.All statistical tests were two-sided, and P values of less
than 0.05 or Bonferroni correction–adjusted P values of
less than 0.05 were considered statistically significant.
Results
Participant characteristics and SNP identification
The HCC patients’ and control participants’ characteristics
are shown in Additional file 1: Table S2. We found no
significant difference in age (P = 0.252) or sex (P = 0.993)
between the HCC patients and controls. Of the HCC
patients, 57.5% had stage I disease, 21.1% had stage II
disease, 12.7% had stage III disease, and 8.7% had stage IV
disease according to the TNM staging system; and 71.1%
had stage A disease, 18.1% had stage B disease, 10.4% had
stage C disease, and 0.3% had stage D disease according
to the BCLC staging system. In the controls, the genotype
distributions of the SNPs in miR-196a2 C > T, miR-499
C > T, and miR-301b A >G (rs11614913, rs3746444, and
rs384262, respectively) were in HWE, but the SNP in
miR-146a C >G (rs2910164) was not (P < 0.001).
After the melting curves were normalized, different
genotypes could be easily distinguished (Figure 1). As
expected, the normalized melting peaks revealed that
the homozygous samples had clearly defined single
peaks for each miRNA SNP (CC or TT peaks for
miR-196a2 C > T and miR-499 C > T; AA or GG peaks
for miR-301b A > G; CC or GG peaks for miR-146a
C > G), and the heterozygous samples had both of the
above described peaks for each mircoRNA SNP. The
results for 30 DNA samples of each SNP randomly
selected for sequencing were fully concordant with HRM,
including all mir-499 CC and mir-146a GG genotype
samples (Figure 2 and Additional file 1: Table S4).
Concordance of SNPs in paired tumor and blood samples
It is unclear if genotypes derived from diseased tissue
produce the same results as those from paired blood
samples. To determine the feasibility of using FFPE
tissue samples as a source of genomic DNA in the study,
we investigated the concordance between genotypes
from 39 paired tumor and blood samples using the κ
statistic, which tests the agreement between two paired
results. κ > 0.80 indicates a good agreement. Our data
demonstrated 100% concordance between the two different
specimens, except a discrepancy in one sample for the
miR-146a SNP (Table 1, Additional file 1: Table S5).
Association of SNPs with HCC risk
After adjustment for confounding factors (sex and age), the
results of the risk estimation analysis based on genotype
distribution, allele frequency, and genetic model by logistic
regression analysis are shown in Table 2. We found
no significant difference in the distributions of the
SNP in miR-301b A >G (rs384262) between the control
Figure 1 HRM genotyping of the four SNPs in miRNA. The normalized melting curves are given in the left column, and the normalized
melting peaks are given in the right column. Arrows indicate the genotype. The representative HRM curves of miR-146a C > G (rs2910164),
miR-196a2 C > T (rs11614913), miR-301b A > G (rs384262), and miR-499 C > T (rs3746444) are shown in A, B, C, and D, respectively.
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of the SNPs in miR-196a2 C > T (rs11614913), miR-499
C > T (rs3746444) and miR146a C > G (rs2910164) in
the HCC patients and controls differed significantly
(P = 0.017, 7 × 10−4 and 0.0015, respectively), which suggests
that these SNPs are correlated with HCC risk.
For the miR-196a2 C > T (rs11614913) polymorphism,
the HCC risk of individuals with TT genotype was
significantly lower than that of individuals with CT
genotype in codominant model (adjusted OR [AOR],
1.95; 95% CI, 1.36-2.81; P = 7 × 10−4) and that of individuals
with either CT or CC genotype in dominant model
(AOR, 1.79; 95% CI, 1.25-2.54; P = 0.0011). We also
found that the HCC risk of individuals with CT genotype
was significantly higher than that of individuals with
either CC or TT genotype in overdominant model
(AOR, 1.77; 95% CI, 1.31-2.41; P = 2 × 10−4).
For the miR-499 C > T (rs3746444) polymorphism,
the HCC risk of individuals with TT genotype was
significantly lower than that of individuals with CT
genotype in codominant model (AOR, 1.79; 95% CI,1.30-2.47; P = 0.0015) and that of individuals with either
CT or CC genotype (AOR, 1.75; 95% CI, 1.27-2.40;
P = 6 × 10−4) in dominant model. We also found that
the HCC risk of individuals with either CC or TT
genotype was significantly lower than that of individ-
uals with CT genotype in overdominant model (AOR,
1.80; 95% CI, 1.30-2.48; P = 3 × 10−4). Additionally, the
minor C allele of miR-499 (rs3746444) was associated
with a higher risk of HCC (AOR, 1.53; 95% CI, 1.15-2.03,
P = 0.003).
For the miR146a C > G (rs2910164) polymorphism,
the HCC risk of individuals with CG genotype was
significantly lower than that of individuals with CC
genotype in codominant model (AOR, 0.71; 95% CI,
0.53-0.96; P = 0.017) and that of individuals with either
CG or GG genotype in dominant model (AOR, 0.70;
95% CI, 0.52-0.95; P = 0.02). Moreover, the HCC risk of
individuals with CG genotype was significantly lower
than that of individuals with either CC or GG genotype
in overdominant model (AOR, 0.72; 95% CI, 0.54-0.97;
P = 0.033).
Figure 2 DNA sequencing of the four SNPs in miRNA. The three genotypes of miR-146a C > G (rs2910164), miR-196a2 C > T (rs11614913), miR-
301b A > G (rs384262), and miR-499 C > T (rs3746444) are shown in A, B, C, and D, respectively.
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were consistent with those of the SNPStats analysis
(special analysis of the SNP online software).
Combined effect of the SNPs associated with HCC risk
To assess the combined effect of the SNPs associated
with HCC risk, we performed a combined analysis of
the SNPs in miR-196a2 and miR-499. The HCC riskof patients who had both unfavorable genotypes was
3.11 times higher than that of patients who had neither
unfavorable genotype (95% CI, 1.89-5.09; P = 7.18 × 10−6)
(Table 3).
SNPs’ effects on HCC patients’ clinical characteristics
We also compared the clinical characteristics of HCC
patients who had different microRNA SNP genotypes.











miR-196a2 1.00 0 39 0
miR-499 1.00 0 39 0
miR-146a 0.96 0.02 (0.95-1.00) 39 1
miR-301b 1.00 0 39 0
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miR-196a2 C > T (rs11614913) had significantly different
clinical characteristics (Table 4). We found that the acti-
vated partial thromboplastin time (APTT) differed among
HCC patients with different miR-196a2 C > T genotypes
(P = 0.032) by one-way ANOVA analysis, and LSD
multiple comparisons indicated that patients with CC
genotype had longer APTT than that of patients with
CT genotype (37.1 ± 8.0 vs. 33.9 ± 7.3, P = 0.011). For the
miR-499 SNP, several patients had CC genotype; therefore,
we combined patients with CT or CC genotype into one
group. We found that the differences in liver function
parameters between patients with TT genotype and
patients with either CT or CC genotype differed signifi-
cantly. Compared with patients who had either CT or CC
genotype, patients with TT genotype had slightly lower
concentrations of direct bilirubin (P = 0.031), globulin
(P = 0.034), γ-glutamyltranspeptidase (P = 0.022), alkaline
phosphatase (P = 0.002), and higher cholinesterase
(P = 0.028) (Table 5). For the miR-146a SNP, compared to
the patients with either CG or GG genotype, patients with
CC genotype had higher albumin-to-globulin ratios
(P = 0.011) (Additional file 1: Table S6). As regard the
miR-301b SNP, neither genotype distributions nor the
34 clinical parameters differed significantly between
the HCC patients and control participants.
Stratified analysis
To examine whether the genotype distributions of the
four SNPs are correlated with patients’ hepatitis B
surface antigen/hepatitis B virus status, we divided the
HCC patients into two groups: hepatitis B virus–positive
(n = 243) and hepatitis B virus–negative (n = 49). We
found no significant difference in the genotype distributions
of the four SNPs between hepatitis B virus–positive and
hepatitis B virus–negative HCC patients (P > 0.05). We also
found no significant association between the TNM or BCLC
tumor stage and the HCC risk of patients with different
genotypes (P > 0.05).
Discussion and conclusions
Because the findings of previous studies regarding the
roles of miRNA SNPs in HCC were inconclusive orinconsistent, they seem to be one of the underpinnings
of the rationale for guiding us in the present study. We
used HRM methods to detect the SNPs of miR-196a2
C > T, miR-499C > T, miR-146a C > G, and miR-301b
A >G in HCC. HRM has been developed for the detection
of DNA sequence variants and it was applied first for
genotyping in 2003 [34], which is a closed-tube method in
which the PCR amplification and can be analyzed in the
same well to detect mutations [35,36]. HRM does not
require post-PCR separation, significant cost savings
are achieved and becomes the most important mutation
detection technique and has been widely applied in
the polymorphisms detection and epigenetics studies
[22,37,38]. HRM analysis was an efficient tool for studies of
SNPs in miRNAs’ SNPs analysis in acute leukemia [39] and
colorectal cancers [22] just two years ago. For evaluating
the sensitivity and specificity of SNP scanning by HRM,
Reed and Wittwer confirmed that the PCR products of
300 bp or less, all the heterozygous and wild-type cases
were correctly called without error. Between 400 and
1000 bp with the mutation centered, the sensitivity and
specificity were 96.1% and 99.4% [40], which indicated that
HRM method would be made our findings more robust
than the previous studies in HCC. We used both logistic
regression analysis and SNPStats to assess the association
between the four SNPs and HCC risk, we found that
the SNPs in miR-196a2 C > T, miR-499 C > T and
miR-146a C > G, but not in miR-301b A > G, in HCC
patients and control participants differed significantly.
Given that the C alleles of miR-196a2 and miR-499 are rela-
tively scarce in Asian populations [11-13,15,16,18,19,33],
we combined the CT and CC as a dominant genotype
model and found that the HCC risk of participants with the
CC or CT genotype was significantly higher than that of
participants with the TTgenotype.
Our study demonstrates that miR-196a2 C > T and
miR-499 C > T increase HCC risk. The HCC risks of
participants who had the variant heterozygous CT genotype
of miR-196a2 or miR-499 were significantly higher than
those of participants who had the wild-type homozygous
TT genotype of miR-196a2 (AOR, 1.95; 95% CI, 1.36–2.81)
or miR-499 (AOR, 1.79; 95% CI, 1.30–2.47). These results
are in agreement with those reported for Chinese HCC
patients. In male Chinese patients with HBV infection, the
risk of HCC was significantly higher in patients with the
CC genotype or carrying C allele for miR-196a2 than those
with the TT genotype or T allele [12]. Similarly, carriers of
miRNA-499 CC were associated with a higher risk of HCC
in Chinese population [13]. Our result also supports a
previous report that common genetic polymorphisms in
miR-196a2 and miR-499 may contribute to breast cancer
susceptibility (OR, 1.23; 95% CI, 1.02-1.48 for miR-196a2;
and OR, 1.25; 95% CI, 1.02-1.51 for miR-499 in a
dominant genetic model) [18]. Additionally, another study
Table 2 Risk estimation based on the distributions of genotype and allele frequency
microRNA Model Genotype Controls n (%) HCCs n (%) AORa (95% CI) P AIC BIC
miR-196a2 Codominant TT 121 (29.8) 60 (19.1) 1.00 7e-04 980.3 1003.2
CT 214 (52.7) 209 (66.6) 1.95 (1.36-2.81)
CC 71 (17.5) 45 (14.3) 1.28 (0.79-2.08)
Dominant TT 121 (29.8) 60 (19.1) 1.00 0.0011 982.3 1000.7
CT + CC 285 (70.2) 254 (80.9) 1.79 (1.25-2.54)
Recessive TT + CT 335 (82.5) 269 (85.7) 1.00 0.26 991.8 1010.1
CC 71 (17.5) 45 (14.3) 0.79 (0.53-1.19)
Overdominant TT + CC 192 (47.3) 105 (33.4) 1.00 2e-04 979.3 997.6
CT 214 (52.7) 209 (66.6) 1.77 (1.31-2.41)
Addictive 1.20 (0.95-1.52) 0.12 990.6 1008.9
Allele T 457 (56.0) 329 (52.0) 1.00 0.156
C 357 (44.0) 299 (48.0) 1.16 (0.94-1.43)
miR-499 Codominant TT 301 (74.1) 195 (62.1) 1.00 0.0015 982.1 1005
CT 101 (24.9) 117 (37.3) 1.79 (1.30-2.47)
CC 4 (1) 2 (0.6) 0.73 (0.13-4.06)
Dominant TT 301 (74.1) 195 (62.1) 1.00 6e-04 981.2 999.5
CT + CC 105 (25.9) 119 (37.9) 1.75 (1.27-2.40)
Recessive TT + CT 402 (99.0) 312 (99.4) 1.00 0.57 992.7 1011
CC 4 (1.0) 2 (0.6) 0.61 (0.11-3.38)
Overdominant TT + CC 305 (75.1) 197 (62.7) 1.00 3e-04 980.2 998.5
CT 101 (24.9) 117 (37.3) 1.80 (1.30-2.48)
Addictive 1.64 (1.21-2.23) 0.0014 982.9 1001.2
Allele T 704 (86.0) 507 (81.0) 1.00 0.003
C 110 (14.0) 121 (19.0) 1.53 (1.15-2.03)
miR-146a Codominant CC 159 (39.2) 149 (47.5) 1.00 0.017 986.8 1009.7
CG 244 (60.1) 165 (52.5) 0.71 (0.53-0.96)
GG 3 (0.7) 0 (0) 0.00 (0.00-NA)
Dominant CC 159 (39.2) 149 (47.5) 1.00 0.02 987.6 1005.9
CG + GG 247 (60.8) 165 (52.5) 0.70 (0.52-0.95)
Recessive CC + CG 403 (99.3) 314 (100) 1.00 0.074 989.8 1008.2
GG 3 (0.7) 0 (0.0) 0.00 (0.00-NA)
Overdominant CC + GG 162 (39.9) 149 (47.5) 1.00 0.033 988.5 1006.8
CG 244 (60.1) 165 (52.5) 0.72 (0.54-0.97)
Addictive 0.69 (0.51-0.93) 0.013 986.9 1005.2
Allele C 564 (69.0) 463 (74.0) 1.00 0.065
G 250 (31.0) 165 (26.0) 0.80 (0.64-1.01)
miR-301b Codominant AA 319 (78.6) 248 (79.0) 1.00 0.96 994.9 1017.8
AG 85 (20.9) 65 (20.7) 1.00 (0.69-1.43)
GG 2 (0.5) 1 (0.3) 0.70 (0.06-7.78)
Dominant AA 319 (78.6) 248 (79.0) 1.00 0.95 993 1011.3
AG + GG 87 (21.4) 66 (21.0) 0.99 (0.69-1.42)
Recessive AA + AG 404 (99.5) 313 (99.7) 1.00 0.77 992.9 1011.3
GG 2 (0.5) 1 (0.3) 0.70 (0.06-7.78)
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Table 2 Risk estimation based on the distributions of genotype and allele frequency (Continued)
Overdominant AA + GG 321 (79.1) 249 (79.3) 1.00 0.99 993 1011.3
AG 85 (20.9) 65 (20.7) 1.00 (0.69-1.44)
Addictive 0.98 (0.69-1.40) 0.92 993 1011.3
Allele A 725 (89.0) 561 (89.0) 1.00 0.872
G 89 (11.0) 67 (11.0) 0.97 (0.70-1.36)
HCC, hepatocellular carcinoma; AOR, adjusted odds ratio; CI, confidence interval; AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion.
NA, not available.
aAdjusted for age and sex.
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model increased the cervical squamous cell carcinoma
risk (OR, 1.78; 95% CI, 1.24–2.56) [23].
Our results also suggested that the HCC risks of
participants with CG genotype of miR-146a were lower
than those with TT genotype (AOR, 0.71; 95% CI,
0.53-0.96). A recent meta-analysis indicated a similar
result that the miR-146a C > G variant was associated
with a decreased HCC risk among Asian populations
[15]. However, several studies reported that miR-146a
C >G was not associated with the risk of HCC [13,33].
Besides, miR-146a could promote cell proliferation and
colony formation in NIH/3T3 [14]. In one study, men
with the GG genotype were twice as susceptible to
HCC as those with the CC genotype (OR, 2.016; 95% CI,
1.056-3.848; P = 0.034); the researchers also found that the
mature miR-146a production of the G-allelic miR-146a
precursor was higher than that of the C-allelic miR-146a
precursor [14]. In addition to HCC, miR-146a C >G has
been associated with cervical squamous cell carcinoma
[23], familial breast/ovarian cancer [24] and thyroid
carcinoma [25]. It should be noted that the genotype
distribution of miR-146a C >G (rs2910164) was not in
HWE. In line with our data, Chu et al. found that miRNA
149 (rs2292832) deviated from HWE in healthy control
participants [27], and another study of 107,000 genotypes
generated from 443 SNPs revealed that the genotype
distributions of 36 of 313 assays (11.5%) were not in
HWE, and the reason for the remaining 10 SNPs deviated
from HWE was unclear [41]. The limitation of this
study is that the reason for the nonconformity ofTable 3 Joint effect of unfavorable SNP genotypes










0 82 (20.2) 39(12.4) 1.00
1 261 (64.1) 177 (56.4) 1.40 (0.91-2.14) 0.126
2 64 (15.7) 98 (31.2) 3.11 (1.89-5.09) 7.18x10−6
AOR, adjusted odds ratio; CI, confidence interval.
aUnfavorable genotypes were potentially risk genotypes (CT + CC for
miR-196a2 and miR-499).
bORs were adjusted for age and sex.miR-146a C > G (rs2910164) genotypes to HWE in
healthy control participants has not been clarified,
further investigation of miR-146a function in HCC
needs to be carried in the future.
In the present study, the distributions of the miR-301b
genotypes in HCC patients and control participants did
not differ significantly. The SNPs of miR-196a2 C > T,
miR-499 C > T, and miR146a C > G are all located in 3p
mature miRNA regions and may influence both the
binding of target mRNAs to 3p and the pre-miRNA
maturation of 5p and 3p. However, the SNP of miR-301b
A >G is located in the miRNA flanking region. This may
explain the lack of a significant difference in the distribu-
tions of the miR-301b genotypes between the two groups;
perhaps this SNP did not change the maturation of the
miR-301b and thus did not influence the binding of target
mRNAs to 3p.
In addition, the clinical characteristics of patients with
different miRNA genotypes were different, and these
characteristics were correlated with different genotypes.
The patients with CC genotype of the miR-196a2 C > T
(rs11614913) had significantly longer APTT. For the
miR-499 C > T (rs3746444), we also demonstrated that
the patients with TT genotype had lower direct bilirubin,
globulin, γ-glutamyltranspeptidase, alkaline phosphatase,
and higher cholinesterase. We firstly verified the differences
in coagulation function and liver function parameters
between patients with TT genotype of the miR-196a2 C >T
(rs11614913) or miR-499 C > T (rs3746444) and the
patients with either CT or CC genotype differed signifi-
cantly. The increased total bilirubin (P < 0.0001) and
decreased albumin (P < 0.0001) were related to poor
prognosis in patients with HCC [42]. On the other
hand, preoperative alkaline phosphatase level could be
utilized to monitor and predict recurrence in high risk
HCC patients [43] and preoperative cholinesterase
levels contributed important information in predicting
postoperative outcome after hepatic resection for HCC,
and cholinesterase ≤ 5,900 U/L independently predicted
the risk of morbidity [44]. These results implied that
miR-196a2 C > T (rs11614913) and miR-499 C > T
(rs3746444) were possibly related to the prognosis
and outcome in patients with HCC.
Table 4 Comparative analysis of the clinical characteristics of hepatocellular carcinoma patients with different
miR-196a2 genotypes
Characteristic Reference intervals TT (n = 60) CT (n = 209) CC (n = 45) P
Alanine amiotransferase (U/L)a 0-46 36.0 (22.8, 60.8) 39.0 (28.0, 78.3) 39.0 (31.0, 78.5) 0.364
Aspartate aminotransferase, (U/L)a 0-46 43.0 (30.0, 62.8) 46.0 (30.3, 85.5) 46.0 (35.0, 72.0) 0.468
Total bilirubin (μmol/L)a 0-25 20.7 (16.0, 29.6) 18.2 (13.0, 24.9) 18.3 (14.9, 24.7) 0.186
Direct bilirubin (μmol/L)a 0-7 5.9 (4.0, 8.5) 4.8 (3.5, 6.8) 5.3 (3.7, 7.1) 0.134
Indirect bilirubin (μmol/L)a 1.5-18 15.2 (11.7, 20.0) 13.7(9.6,18.9) 12.7 (9.5, 17.1) 0.227
Total protein (g/L)a 60-80 69.5 (64.4, 73.8) 68.1 (62.2, 74.0) 67.1 (61.7, 71.3) 0.215
Albumin (g/L)b 35-55 40.3 ± 5.0 40.4 ± 6.0 38.8 ± 6.8 0.266
Globulin (g/L)a 20-30 29.5 (24.8, 31.9) 27.5 (23.5, 30.6) 26.7 (23.2, 29.8) 0.112
Albumin/Globulina 1.5-2.5 1.4 (1.3, 1.6) 1.5 (1.3, 1.7) 1.5 (1.2, 1.7) 0.316
γ-glutamyltransferase (U/L)a 5-55 60.5 (39.8, 134.5) 62.0 (39.3, 118.0) 67.5 (31.3, 97.5) 0.716
Alkaline phosphatase (U/L)a 35-134 93.0 (71.8, 113.3) 102.0 (78.0, 137.0) 91.0 (77.0, 110.8) 0.170
5-Nucleotidase (U/L)a 0-10 3.5 (2.0, 5.8) 3.0 (2.0, 6.0) 3.0 (2.0, 4.5) 0.403
Total biliary acid (μmol/L)a 0-15 7.4 (4.0, 22.4) 7.1 (3.6, 15.6) 7.1(4.0,14.7) 0.553
Cholinesterase (U/L)a 3000-10500 5940.8 ± 2522.3 6074.5 ± 2231.3 6007.5 ± 2498.1 0.927
Pre-albumin (mg/L)a 100-400 119.5 (68.8, 157.9) 118.0 (75.0, 175.3) 110.0 (56.0, 172.5) 0.493
Glucose (mmol/L)a 3.9-6.2 5.0 (4.4, 6.0) 5.1 (4.6, 5.8) 5.1 (4.4, 5.6) 0.653
Blood urea nitrogen (mmol/L)a 1.7-7.2 4.9 (3.5, 5.7) 5.0 (3.8, 6.0) 5.2 (3.3, 6.2) 0.633
Creatinine (μmol/L)a 45-117 76.2 (69.1, 83.7) 73.5 (64.1, 84.0) 72.2 (62.7, 83.7) 0.488
Uric acid (μmol/L)b 119-417 243.0 ± 77.3 257.3 ± 92.8 251.7 ± 72.9 0.547
Retinol-binding protein (mg/L)a 15-70 25.4 (16.1, 34.5) 28.1 (17.4, 35.0) 27.2 (16.3, 35.7) 0.990
Cystatin C (mg/L)a 0-1.2 1.1 (0.8, 1.2) 1.0 (0.9, 1.2) 1.0 (0.9, 1.2) 0.999
Carcinoembryonic antigen, (ng/mL)a 0-5 2.0 (1.6, 2.9) 2.3 (1.4, 3.5) 2.2 (1.8, 3.3) 0.683
Alpha-fetoprotein (ng/mL)a 0-20 124.1 (9.8, 865.8) 130.7 (8.5, 957.9) 382.4 (36.2, 1052.0) 0.116
Ferritin (ng/mL)a 0-322 353.0 (138.9, 431.3) 204.5 (116.7, 342.0) 232.9 (174.6, 392.0) 0.281
Cancer antigen 125 (KU/L)a 0-35 12.8 (8.7, 38.3) 15.5 (9.6, 32.5) 17.3 (9.9, 58.2) 0.701
Cancer antigen 153 (KU/L)a 0-35 11.5 (9.6, 16.0) 9.3 (7.5, 13.6) 10.6 (7.8, 17.2) 0.206
Cancer antigen 199 (KU/L)a 0-35 13.3 (8.0, 23.1) 13.3 (6.4, 26.3) 12.8 (6.6, 17.2) 0.779
Prothrombin time (sec)a 10.5-13.5 12.0 (11.4, 13.2) 11.9 (11.0, 12.9) 12.2 (11.3, 13.2) 0.462
PT% (%)a 80-130 94.5 (84.2, 100.7) 91.3 (81.6, 109.4) 91.0 (77.2, 101.1) 0.603
International standard ratioa 0.85-1.15 1.0 (1.0, 1.2) 1.0 (1.0, 1.1) 1.1 (1.0, 1.1) 0.437
D-fibrinogen (g/L)a 2-4 2.5 (2.2, 3.2) 2.8 (2.2, 3.5) 2.5 (2.1, 3.1) 0.348
activated partial thrombo -plastin time (sec)b 28-40 35.2 ± 7.6 33.9 ± 7.3 37.1 ± 8.0 0.032
Thrombin time (sec)a 11-14 14.4 (13.6, 15.7) 14.4 (13.7, 15.4) 14.5(13.7,16.0) 0.872
aData were expressed as median (25th percentile, 75th percentile).
bData were expressed as mean ± SD.
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miR-499C > T increased HCC risk, and different genotypes
of the SNPs in three miRNAs affected the clinical labora-
tory characteristics of HCC patients. It is the first study to
demonstrate the relationship between different genotypes
and the clinical laboratory characteristics of HCC patients.
Future studies should identify the specific mechanism
underlying miR-196a2C >T and miR-499 C > T genotypes
as well as altered clinical laboratory characteristics, whichshould provide valuable information facilitating the early
detection and diagnosis of HCC.
It is well known that cancer tissues show frequent
mutations even at SNP sites and the sequence variations
in tumor tissues maybe be different from those of normal
blood samples, which will almost certainly lead to questions
of how to justify the tissue-with-blood comparisons.
However, in this study, we compared the reliability of
genetic studies done on biobanks comprised of FFPE
Table 5 Comparative analysis of the clinical characteristics of hepatocellular carcinoma patients with different miR-499
genotypes
Characteristic Reference intervals TT (n = 195) CT + CC (n = 119) P
Alanine amiotransferase (U/L)a 0-46 38.0 (28.0, 66.0) 39.5 (28.3, 90.3) 0.470
Aspartate aminotransferase, (U/L)a 0-46 44.0 (30.0, 68.0) 47.0 (32.3, 90.3) 0.385
Total bilirubin (μmol/L)a 0-25 18.7 (13.3, 25.4) 19.1 (14.3, 27.9) 0.615
Direct bilirubin (μmol/L)a 0-7 4.7 (3.4, 6.6) 5.5 (4.1, 8.5) 0.031
Indirect bilirubin (μmol/L)a 1.5-18 13.9 (9.7,1 8.6) 14.2 (10.0, 19.1) 0.965
Total protein (g/L)a 60-80 68.0 (61.5, 73.2) 68.6 (63.6, 74.1) 0.307
Albumin (g/L)b 35-55 40.4 ± 6.2 39.8 ± 5.5 0.378
Globulin (g/L)a 20-30 27.1 (23.5, 30.3) 29.1 (24.9, 32.1) 0.034
Albumin/Globulina 1.5-2.5 1.5 (1.3, 1.7) 1.4 (1.3, 1.7) 0.099
γ-glutamyltransferase (U/L)a 5-55 55.0 (40.0, 99.0) 73.0 (37.0, 191.0) 0.022
Alkaline phosphatase (U/L)a 35-134 92.0 (74.0, 120.0) 108.5 (84.5, 136.8) 0.002
5-Nucleotidase (U/L)a 0-10 3.0 (2.0, 5.0) 3.0 (2.0, 7.5) 0.236
Total biliary acid (μmol/L)a 0-15 6.9 (3.5, 13.9) 9.3 (4.5, 19.4) 0.149
Cholinesterase (U/L)a 3000-10500 6264.2 ± 2351.8 5645.5 ± 2225.7 0.028
Pre-albumin (mg/L)a 100-400 125.5 (69.7, 168.9) 100.0 (70.0, 176.3) 0.374
Glucose (mmol/L)a 3.9-6.2 5.0 (4.5, 5.8) 5.2 (4.7, 5.9) 0.085
Blood urea nitrogen (mmol/L)a 1.7-7.2 5.0 (3.5, 5.8) 5.1 (3.9, 6.4) 0.187
Creatinine (μmol/L)a 45-117 73.8 (65.5, 84.0) 73.8 (61.9, 83.7) 0.187
Uric acid (μmol/L)b 119-417 252.0 ± 87.4 256.9 ± 87.3 0.642
Retinol-binding protein (mg/L)a 15-70 28.0 (17.9, 34.6) 27.9 (15.9, 38.2) 0.695
Cystatin C (mg/L)a 0-1.2 1.1 (0.9, 1.2) 1.0 (0.9, 1.3) 0.782
Carcinoembryonic antigen,(ng/mL)a 0-5 2.1 (1.4, 3.4) 2.3 (1.6, 1.9) 0.365
Alpha-fetoprotein (ng/mL)a 0-20 181.7 (10.9, 1000.0) 99.2 (8.4, 691.2) 0.164
Ferritin (ng/mL)a 0-322 196.8 (126.7, 361.2) 277.9 (161.0, 424.6) 0.212
Cancer antigen 125 (KU/L)a 0-35 15.2 (10.1, 31.7) 16.0 (8.6, 45.5) 0.707
Cancer antigen 153 (KU/L)a 0-35 10.4 (7.6, 14.1) 9.6 (7.3, 14.3) 0.720
Cancer antigen 199 (KU/L)a 0-35 13.3 (7.1, 23.7) 12.4 (6.6, 26.8) 0.585
Prothrombin time (sec)a 10.5-13.5 12.0 (11.3, 12.8) 11.9 (10.9, 13.2) 0.875
PT% (%)a 80-130 91.3 (82.0, 104.0) 93.5 (79.8, 109.0) 0.744
International standard ratioa 0.85-1.15 1.0 (1.0, 1.1) 1.0 (1.0, 1.2) 0.815
D-fibrinogen (g/L)a 2-4 2.7 (2.2, 3.4) 2.6 (2.3, 3.3) 0.724
activated partial thrombo-plastin time (sec)b 28-40 34.8 ± 7.3 34.3 ± 7.9 0.568
Thrombin time (sec)a 11-14 14.4 (13.8, 15.5) 14.5 (13.5, 15.5) 0.886
aData were expressed as median (25th percentile, 75th percentile).
bData were expressed as mean ± SD.
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http://www.biomedcentral.com/1471-2407/14/643autopsy tissue with banks of blood samples from the
same donors, and investigated the association of four
miRNAs’ SNPs with HCC risk. Our data suggested that
the genotypes of miRNA’s SNPs were almost identical in
HCC tissue and peripheral blood samples from the same
patients (n = 39). The similar results were performed by
Sjöholm et al., which showed that DNA from all plasma
(n = 30, HCC patients) and serum (n = 1, additional
patient) samples gave identical genotyping results asobtained from tissue DNA from the same subject by
comparison of archival plasma and FFPE tissue for
genotyping in HCC, who also reported 100% each-way
matching [45].
Finally, our results were based on a small sample size.
Further validation of these findings is warranted in larger
studies. We will collect more FFPE tissue and blood
samples from HCC patients to further address the clinical
utility of the miRNA SNPs for the risk prediction of HCC.
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